Ariz Precision Medicine
ARIZ: Developing early-stage cancer drug candidates for effective disease eradication.
Founded
2015ARIZ: Developing early-stage cancer drug candidates for effective disease eradication.
Founded with a mission to eradicate cancer at its earliest stages, Ariz Precision Medicine focuses on developing innovative drug candidates that target the root causes of cancer. Utilizing a combination of biological and nanotechnologies, Ariz aims to prevent cancer growth and metastasis. Their core vision is to leverage precision medicine to create highly effective, individualized treatments for cancer patients, addressing the disease when it is most easily treatable.
Ariz Precision Medicine has garnered attention for its unique approach and promising early-stage drug candidates. The company is supported by a team of experts in oncology and biotechnology, and has attracted investment from leading venture capital firms specializing in healthcare innovation. Notable achievements include successful preclinical trials demonstrating the efficacy of their drug candidates. Ariz's impact lies in its potential to revolutionize cancer treatment, offering hope for more effective and personalized therapies.
Companies similar to Ariz Precision Medicine include Zephyr AI, Aria Pharmaceuticals, OncoPrecision and Alphina Therapeutics.
Ariz Precision Medicine was founded in 2015.
Ariz Precision Medicine's headquarters is located in Davis, CA, US.
Ariz Precision Medicine's most recent funding round was for $1M (USD) in March 2022.
As of Mar 16, 2022, Ariz Precision Medicine has disclosed funding of $2.7M (USD). Undisclosed round amounts are excluded.
Ariz Precision Medicine has 2 employees as of Feb 5, 2024.
Alphina Therapeutics
